Twist Bioscience Co. (NASDAQ:TWST) Shares Acquired by D.A. Davidson & CO.

D.A. Davidson & CO. increased its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 3.5% during the 3rd quarter, Holdings Channel.com reports. The firm owned 19,618 shares of the company’s stock after buying an additional 664 shares during the quarter. D.A. Davidson & CO.’s holdings in Twist Bioscience were worth $886,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. raised its stake in shares of Twist Bioscience by 210.2% in the 2nd quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock worth $6,057,000 after buying an additional 83,287 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Twist Bioscience by 215.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after purchasing an additional 20,035 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Twist Bioscience by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 32,127 shares of the company’s stock valued at $1,103,000 after purchasing an additional 2,292 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in Twist Bioscience during the second quarter worth approximately $402,000. Finally, Calamos Advisors LLC bought a new stake in Twist Bioscience during the second quarter worth approximately $281,000.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $49.18 on Monday. Twist Bioscience Co. has a twelve month low of $23.25 and a twelve month high of $60.90. The firm has a market cap of $2.92 billion, a PE ratio of -13.66 and a beta of 1.78. The firm’s 50 day moving average price is $43.84 and its two-hundred day moving average price is $46.23.

Analysts Set New Price Targets

A number of brokerages have recently commented on TWST. Leerink Partners increased their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Barclays decreased their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. TD Cowen restated a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. JPMorgan Chase & Co. raised their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Finally, Scotiabank boosted their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $51.00.

Insider Activity

In other news, CEO Emily M. Leproust sold 1,730 shares of the firm’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $46.94, for a total transaction of $81,206.20. Following the completion of the sale, the chief executive officer now directly owns 495,523 shares of the company’s stock, valued at $23,259,849.62. This trade represents a 0.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Dennis Cho sold 1,507 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $72,336.00. Following the completion of the sale, the insider now directly owns 91,163 shares of the company’s stock, valued at approximately $4,375,824. The trade was a 1.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 98,118 shares of company stock worth $4,391,151 in the last ninety days. Corporate insiders own 3.92% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.